Cynata Therapeutics Limited
Climate Impact & Sustainability Data (2018, 2018-07-01 to 2018-12-31, 2018-09)
Reporting Period: 2018
Environmental Metrics
Social Achievements
- Completed first in-human trial of CymerusTM MSCs, treating 15 patients with acute graft-versus-host disease
Climate Goals & Targets
Short-term Goals:
- Commence Phase II GvHD trial
- Commence Phase II trial in Critical Limb Ischemia
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2018-07-01 to 2018-12-31
Environmental Metrics
Social Achievements
- Successful completion of the Company’s first clinical trial with all end points met and clear demonstration of efficacy of Cymerus™ MSC product CYP-001 in graft-versus-host disease (GvHD).